DB:2UO1

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Happiness Biotech Group

Executive Summary

Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People’s Republic of China and internationally. More Details


Snowflake Analysis

Undervalued with excellent balance sheet.


Similar Companies

Share Price & News

How has Happiness Biotech Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2UO1 is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 2UO1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.


Market Performance


7 Day Return

0.6%

2UO1

0.1%

DE Personal Products

1.4%

DE Market


1 Year Return

n/a

2UO1

5.9%

DE Personal Products

0.9%

DE Market

Return vs Industry: Insufficient data to determine how 2UO1 performed against the German Personal Products industry.

Return vs Market: Insufficient data to determine how 2UO1 performed against the German Market.


Shareholder returns

2UO1IndustryMarket
7 Day0.6%0.1%1.4%
30 Day12.1%2.7%8.7%
90 Day-10.3%6.8%2.3%
1 Yearn/a8.1%5.9%4.1%0.9%
3 Yearn/a36.9%27.7%3.9%-5.1%
5 Yearn/a69.8%51.4%24.8%7.1%

Long-Term Price Volatility Vs. Market

How volatile is Happiness Biotech Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Happiness Biotech Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2UO1 (€1.57) is trading below our estimate of fair value (€3.95)

Significantly Below Fair Value: 2UO1 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2UO1 is good value based on its PE Ratio (3.6x) compared to the XE Personal Products industry average (20.8x).

PE vs Market: 2UO1 is good value based on its PE Ratio (3.6x) compared to the German market (23.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2UO1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2UO1 is good value based on its PB Ratio (0.6x) compared to the XE Personal Products industry average (2.4x).


Next Steps

Future Growth

How is Happiness Biotech Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

9.6%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Happiness Biotech Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Happiness Biotech Group performed over the past 5 years?

-32.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2UO1 has high quality earnings.

Growing Profit Margin: 2UO1's current net profit margins (19.5%) are lower than last year (29.3%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2UO1's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: 2UO1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2UO1 had negative earnings growth (-32.2%) over the past year, making it difficult to compare to the Personal Products industry average (16.3%).


Return on Equity

High ROE: 2UO1's Return on Equity (15.9%) is considered low.


Next Steps

Financial Health

How is Happiness Biotech Group's financial position?


Financial Position Analysis

Short Term Liabilities: 2UO1's short term assets ($70.0M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: 2UO1 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 2UO1's debt to equity ratio (2.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 2UO1's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 2UO1's debt is well covered by operating cash flow (530.3%).

Interest Coverage: 2UO1's interest payments on its debt are well covered by EBIT (665x coverage).


Balance Sheet


Next Steps

Dividend

What is Happiness Biotech Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2UO1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2UO1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2UO1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2UO1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2UO1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average board tenure


CEO

Xuezhu Wang (36 yo)

2.25yrs

Tenure

US$25,587

Compensation

Mr. Xuezhu Wang has been Chief Executive Officer of Happiness Biotech Group Limited since August 28, 2018 and Executive Director since February 09, 2018. He has been the Chief Executive Officer of Fujian H...


CEO Compensation Analysis

Compensation vs Market: Xuezhu's total compensation ($USD25.59K) is below average for companies of similar size in the German market ($USD471.21K).

Compensation vs Earnings: Xuezhu's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Xuezhu Wang
CEO & Director2.25yrsUS$25.59k46.51%
$ 19.5m
Jonathan F. Levy
Independent Director1.08yrsno datano data
Wanhe Zhang
Independent Director1.08yrsno data1.33%
$ 559.2k
Rui Qiang
Independent Director1.08yrsno datano data
Wenhui Lin
Directorno datano datano data

1.1yrs

Average Tenure

51yo

Average Age

Experienced Board: 2UO1's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.


Top Shareholders

Company Information

Happiness Biotech Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Happiness Biotech Group Limited
  • Ticker: 2UO1
  • Exchange: DB
  • Founded: 2004
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$49.987m
  • Listing Market Cap: US$41.984m
  • Shares outstanding: 25.90m
  • Website: https://www.happ.org.cn

Number of Employees


Location

  • Happiness Biotech Group Limited
  • No. 11, Dongjiao East Road
  • Shuangxi
  • Nanping
  • Fujian Province
  • 353200
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HAPPNasdaqCM (Nasdaq Capital Market)YesOrdinary SharesUSUSDOct 2019
2UO1BST (Boerse-Stuttgart)YesOrdinary SharesDEEUROct 2019
2UO1DB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2019

Biography

Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People’s Republic of China and internationally. The compa...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 18:35
End of Day Share Price2020/11/25 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.